Surgical and Pharmacological Efficacy of Knosp Grade 0-2 Prolactinoma
NCT ID: NCT06556186
Last Updated: 2024-08-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
600 participants
INTERVENTIONAL
2024-10-01
2027-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Application Research on Endoscopic Pseudocapsule-Based Resection for Pituitary Adenomas
NCT05466357
Endocrine Outcome of Surgery for Pituitary Adenoma
NCT03515603
Validation of a Quality of Life Metric "Prolac-10"
NCT04106531
Nasal Irrigation Apply in Patients After Transsphenoidal Pituitary Tumor Resection
NCT03933241
Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus
NCT02536261
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Operation group
Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy
Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy
Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy
Drug group
Bromocriptin 2.5mg, 2-3 times a day
Bromocriptin 2.5mg, 2-3 times a day
Bromocriptin 2.5mg, 2-3 times a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy
Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy
Bromocriptin 2.5mg, 2-3 times a day
Bromocriptin 2.5mg, 2-3 times a day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* MRI indicates Knosp Grade 0-2 pituitary adenoma
Exclusion Criteria
* Taking antidepressants or other psychotropic drugs
* Patients allergic to bromocriptine or cannot tolerate surgery
* Women defined as surgical infertility (i.e. hysterectomy, bilateral salpingectomy, or bilateral oophorectomy), or amenorrhea for more than 2 years
* Critical illness patients, such as those with progressive consciousness disorders, cerebral hernias, and other emergency situations
20 Years
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking Union Medical College Hospital
OTHER
West China Hospital
OTHER
First Affiliated Hospital of Wenzhou Medical University
OTHER
Ningbo Medical Center Lihuili Hospital
OTHER_GOV
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-0268
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.